The quarter fell short of both the company’s own setup and published expectations. Sales of $70.4 million came in just below the prior $70.5 million–$72.5 million guide and below the roughly $72 million published consensus; diluted EPS of $0.74 missed both the prior $0.79–$0.84 guide and the published $0.81 consensus. That outweighs the otherwise healthy year-over-year growth in operating income and margin. (Business Outlook; Income Statement)
| Metric | Q2 2026 actual | Prior-year Q2 | Pre-result expectation / prior outlook | What changed |
|---|---|---|---|---|
| Sales | $70.4mm | $64.2mm | $70.5mm–$72.5mm guide; published consensus about $72mm | Below the low end of guidance |
| Diluted EPS | $0.74 | $0.60 | $0.79–$0.84 guide; published consensus $0.81 | Below guidance and consensus |
| Gross margin | 72.1% | 70.0% | — | +210 bps year over year |
| Operating income | $20.4mm | $16.1mm | — | +26% year over year |
| FY 2026 sales guide, midpoint | $276.3mm | — | Prior midpoint $280.0mm | Cut by $3.7mm |
| FY 2026 EPS guide, midpoint | $2.89 | — | Prior midpoint about $3.01 | Cut by about $0.12 |
The more consequential news is the reset to the second half. Full-year sales guidance moved to a $274.3 million–$278.3 million range from the prior $277 million–$283 million range, while EPS moved to $2.84–$2.94 from $2.93–$3.08. The new midpoint implies only 10% reported sales growth in Q3 and $0.69 EPS, so the filing lowers the near-term earnings path rather than simply reporting a one-quarter timing miss. (Business Outlook)
Underlying product and margin trends remain solid, but did not prevent the downgrade. Artegraft sales rose 34%, with grafts up 23% and international regions up 18% in both EMEA and APAC; excluding the catheter comparison distorted by prior-year recall-related stocking, organic sales growth was 12%. Gross margin expanded to 72.1% on pricing, mix, and operating efficiencies. Those are constructive operating indicators, but the market had already expected a stronger revenue and EPS outcome. (Financial Highlights; Selected Net Sales Information; Reconciliation of GAAP to Non-GAAP Sales Growth)
Liquidity is a support, not an offset to the earnings miss. Cash plus short-term marketable securities reached $376.2 million, up $9.0 million sequentially, while six-month operating cash flow rose to $31.1 million from $29.3 million. The $0.25 quarterly dividend continues the prior rate; it is not a new positive surprise. (Financial Highlights; Balance Sheets; Cash Flow Statement; Quarterly Dividend)
Read the original 8-K on SEC EDGAR ↗